PureTech Health plc Stock
Stocks
PRTC
GB00BY2Z0H74
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 119.60 GBX | -1.16% |
|
-3.08% | -4.32% |
| 07-13 | PureTech Health announces first patient dosing in Celea phase 3 trial | AN |
| 07-13 | PureTech Health: Celea Therapeutics Kicks Off Late-stage Trial for Idiopathic Pulmonary Fibrosis Drug | MT |
| Market Cap | 391M 344M 321M 295M 551M 37.48B 565M 3.81B 1.49B 18.55B 1.47B 1.44B 64.11B | P/E 2026 * |
-3.52x | P/E 2027 * | -4.2x |
|---|---|---|---|---|---|
| Enterprise Value | 122M 108M 100M 92.1M 172M 11.72B 177M 1.19B 465M 5.8B 459M 449M 20.05B | EV / Sales 2026 * |
17.2x | EV / Sales 2027 * | 10.9x |
| Free-Float |
84.53% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: PureTech Health plc
| 1 day | -1.24% | ||
| 1 week | -3.08% | ||
| Current month | -12.95% | ||
| 1 month | -12.95% | ||
| 3 months | -6.27% | ||
| 6 months | -9.67% | ||
| Current year | -4.32% |
| 1 week | 117.4 |  | 124.2 |
| 1 month | 115 | | 139 |
| Current year | 107.4 | | 143.6 |
| 1 year | 104.71 | | 146.4 |
| 3 years | 100.4 | | 238.5 |
| 5 years | 100.4 | | 410.66 |
| 10 years | 100.4 | | 447.66 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Lyne
CEO | Chief Executive Officer | 43 | 15/07/2025 |
Eric Elenko
PSD | President | 53 | 09/04/2024 |
Charles Sherwood
COO | Chief Operating Officer | - | 01/08/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Langer
BRD | Director/Board Member | 76 | 08/05/2015 |
John LaMattina
BRD | Director/Board Member | 76 | 01/01/2009 |
| Director/Board Member | 73 | 01/10/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 9/24/25 A | Buy | Chief Executive Officer | 81,051 | 0.0337% | ||
| 9/24/25 A | Buy | Director | 29,239 | 0.0122% | ||
| 9/24/25 A | Buy | Chairman | 65,250 | 0.0272% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.16% | -3.08% | -17.40% | -46.49% | 391M | |
| -0.80% | +5.16% | -0.70% | +12.87% | 48.95B | |
| -4.04% | +13.93% | +23.31% | +5.56% | 40.75B | |
| +3.61% | -1.09% | +404.36% | +611.20% | 38.46B | |
| -2.35% | -2.66% | +6.05% | +48.48% | 36.38B | |
| +5.56% | +11.70% | +11.64% | +51.50% | 28.45B | |
| -1.27% | -2.14% | - | - | 16.62B | |
| -1.21% | -5.05% | +31.40% | +127.21% | 16.33B | |
| -5.40% | -1.93% | -7.97% | -33.56% | 13.65B | |
| -0.06% | +3.75% | +3.81% | +9.62% | 13.56B | |
| Average | -0.63% | +5.20% | +50.50% | +87.38% | 25.35B | |
| Weighted average by Cap. | -0.27% | +7.18% | +73.73% | +123.78% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.1M 6.24M 5.82M 5.34M 10M 680M 10.25M 69.05M 27.01M 337M 26.66M 26.08M 1.16B | 13.47M 11.83M 11.05M 10.14M 18.98M 1.29B 19.44M 131M 51.22M 638M 50.56M 49.46M 2.21B |
| Net income | -124M -109M -102M -93.41M -175M -11.89B -179M -1.21B -472M -5.88B -466M -456M -20.33B | -96.8M -85.06M -79.4M -72.86M -136M -9.27B -140M -941M -368M -4.59B -363M -356M -15.86B |
| Net Debt | -269M -236M -221M -202M -379M -25.76B -388M -2.62B -1.02B -12.75B -1.01B -988M -44.07B | -244M -215M -200M -184M -344M -23.41B -353M -2.38B -929M -11.58B -917M -898M -40.04B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/07/26 | GBX 119.60 | -1.16% | 365,375 |
| 29/07/26 | GBX 121.00 | +2.37% | 926,652 |
| 28/07/26 | GBX 118.20 | -3.11% | 419,236 |
| 27/07/26 | GBX 122.00 | -0.81% | 328,816 |
| 24/07/26 | GBX 123.00 | -0.32% | 301,399 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PRTC Stock
Select your edition
All financial news and data tailored to specific country editions
